Benzinga | Nov 16, 2021 04:41AM EST

Stephens & Co. Initiates Coverage On Anika Therapeutics with Overweight Rating, Announces Price Target of $55

Stephens & Co. analyst Chris Cooley initiates coverage on Anika Therapeutics (NASDAQ:ANIK) with a Overweight rating and announces Price Target of $55.